全文获取类型
收费全文 | 5284篇 |
免费 | 306篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 128篇 |
妇产科学 | 53篇 |
基础医学 | 835篇 |
口腔科学 | 140篇 |
临床医学 | 500篇 |
内科学 | 1154篇 |
皮肤病学 | 161篇 |
神经病学 | 523篇 |
特种医学 | 248篇 |
外科学 | 753篇 |
综合类 | 21篇 |
一般理论 | 2篇 |
预防医学 | 285篇 |
眼科学 | 48篇 |
药学 | 395篇 |
中国医学 | 3篇 |
肿瘤学 | 319篇 |
出版年
2023年 | 22篇 |
2022年 | 45篇 |
2021年 | 98篇 |
2020年 | 74篇 |
2019年 | 96篇 |
2018年 | 147篇 |
2017年 | 112篇 |
2016年 | 144篇 |
2015年 | 115篇 |
2014年 | 156篇 |
2013年 | 237篇 |
2012年 | 305篇 |
2011年 | 325篇 |
2010年 | 219篇 |
2009年 | 205篇 |
2008年 | 325篇 |
2007年 | 334篇 |
2006年 | 292篇 |
2005年 | 276篇 |
2004年 | 258篇 |
2003年 | 260篇 |
2002年 | 229篇 |
2001年 | 67篇 |
2000年 | 71篇 |
1999年 | 69篇 |
1998年 | 53篇 |
1997年 | 45篇 |
1996年 | 31篇 |
1995年 | 26篇 |
1994年 | 35篇 |
1993年 | 22篇 |
1992年 | 39篇 |
1991年 | 42篇 |
1990年 | 42篇 |
1989年 | 44篇 |
1988年 | 33篇 |
1987年 | 32篇 |
1986年 | 33篇 |
1985年 | 35篇 |
1984年 | 43篇 |
1983年 | 30篇 |
1982年 | 26篇 |
1980年 | 23篇 |
1979年 | 26篇 |
1978年 | 40篇 |
1977年 | 31篇 |
1975年 | 22篇 |
1974年 | 22篇 |
1972年 | 21篇 |
1971年 | 22篇 |
排序方式: 共有5622条查询结果,搜索用时 11 毫秒
101.
102.
Purpose of review
Platelet-rich plasma has become an increasingly popular treatment option within the orthopedic community to biologically enhance and stimulate difficult-to-heal musculoskeletal tissues. This review evaluates the recent literature on platelet-rich plasma use in the treatment of foot and ankle pathologies.Recent findings
Recent literature has demonstrated platelet-rich plasma to have a possible benefit in the treatment of Achilles pathology, chronic plantar fasciitis, osteochondral lesions of the talus, ankle osteoarthritis, and diabetic foot ulcers. However, given the lack of standardization of platelet-rich plasma preparations and protocols and the predominance of low-quality studies, no definitive treatment indications exist.Summary
Platelet-rich plasma is a promising treatment option, but at present, there is only limited clinical evidence supporting its use in foot and ankle applications.103.
Introduction
The objective of this prospective, multicenter, parallel-group, non-interventional clinical trial (NIT) was to characterize the effectiveness of a treatment with the phytomedicines ELOM-080 and BNO 1016 in patients with acute rhinosinusitis (ARS).Methods
A total of 228 patients suffering from ARS took part in this NIT and were treated for a maximum of 14 days with either BNO 1016 or ELOM-080. Focus was on improvement of rhinosinusitis-associated pain/discomfort and nasal congestion in real-life conditions of primary care setting, as assessed by numeric and verbal rating scale, and five-point Likert scale.Results
The course of the key ARS symptom facial pain demonstrated a faster recovery in patients with ELOM-080, when compared to BNO 1016. ELOM-080 tended to be superior for several ancillary criteria and induced significantly higher patient satisfaction with regard to the improvement of feeling of general illness. Physicians assessed both products to be very effective and well tolerated. Adverse drug reactions classified as gastrointestinal disorders occurred in both groups to a comparable extent.Conclusion
This trial demonstrated comparable effectiveness of a therapy of ARS with the phytomedicines ELOM-080 and BNO 1016, although the treatment with ELOM-080 resulted in a more rapid and more complete recovery in ARS key symptoms and tended to be superior for several ancillary criteria. Both treatments were well tolerated.Trial registration number
NIS-6471.Funding
G. Pohl-Boskamp GmbH & Co. KG.104.
105.
With a special technique 4-13 consecutive fractions of urine were collected during micturition from 4 female volunteers at together 12 occasions. Quantitative bacterial cultures were performed in 78 urine fractions. Most fractions contained one or several different bacterial strains-generally in small amounts, wheras only 14% were sterile. Fractions from the end of micturition showed on average less bacterial contamination than the earlier portions. No difference was observed between the bacterial counts after cleaning the area around the urethra as compared with the counts without preparation before sampling. 相似文献
106.
Previous investigations in our unit indicated that acute cardiogenic pulmonary edema is associated not only with an increase in left ventricular end-diastolic pressure and pulmonary arterial wedge pressure but also with a relative increase in colloid osmotic (oncotic) pressure and peripheral hemoglobin concentration. This combination of changes suggested that acute congestive heart failure with pulmonary edema, unlike chronic congestive heart failure, is associated with a contraction of intravascular blood volume. In this study, plasma volume changes were measured before and during the treatment of acute cardiogenic pulmonary edema in 14 patients with arteriosclerotic heart disease. The plasma volume measurement in all 14 patients before the initiation of treatment was either normal or decreased. After treatment with the alpha adrenergic blocking agent phentolamine, the plasma volume increased rather than decreased when measured 4 and 12 hours after the initiation of treatment. During this time colloid osmotic pressure and peripheral hemoglobin concentration progressively decreased. These findings suggest that acute cardiogenic pulmonary edema is associated with the extravasation of large quantities of plasma water from the intravascular compartment into the interstitial compartment and contraction of the intravascular plasma volume. The treatment of acute cardiogenic pulmonary edema is associated with the return of hypo-oncotic fluid from the interstitial compartment back into the intravascular compartment with expansion of plasma volume and reduction of colloid osmotic pressure and hemoglobin concentration. 相似文献
107.
Frank-Raue K Machens A Scheuba C Niederle B Dralle H Raue F;German MEN Study Group 《Clinical endocrinology》2008,69(2):259-263
Objectives Hereditary medullary thyroid carcinoma (MTC) is caused by germ‐line mutations in the RET proto‐oncogene. Our study addresses the difference in development of MTC between rare mutations in RET codons 790, 791 and 804. Design We evaluated tumour stage, calcitonin levels, biochemical cure rates and associated endocrinopathies in 153 German/Austrian patients with RET 790 (n = 47), 791 (n = 56) and 804 mutations (n = 50), divided into index‐ and screening groups. Results Age at diagnosis in index‐patients did not differ significantly among the three codon groups (medians of 57, 61 and 53 years). Tumour stage at diagnosis was significantly less advanced with codon 791 (n = 22) than 790 (n = 16) and 804 (n = 16) mutations (P = 0·001). In screening patients, age at diagnosis did not differ significantly among the three groups (medians 19, 24 and 32 years). Tumour stage at diagnosis was also significantly less advanced with codon 791 (n = 34) than 790 (n = 31) and 804 (n = 34) (P = 0·032). Preoperative basal calcitonin levels were significantly lower in codon 791 carriers compared to codon 790 carriers, and cure rates were significantly higher in both index (75%vs. 31%; P = 0·03) and screening patients (100%vs. 75%; P = 0·015). Additional endocrinopathies were observed only with codon 791 carriers (four pheochromocytomas and two hyperparathyroidism). Conclusion There is a significant difference in MTC development with less extensive C‐cell disease, higher cure rate and more frequent additional endocrinopathies in carriers of RET codon 791 mutations compared with carriers of codons 790 and 804 mutations. This information should be considered when age of prophylactic thyroidectomy is discussed. 相似文献
108.
109.
Colin W. Howden M.D. F.A.C.G. James M. Henning M.S. Bidan Huang Ph.D. Nancy Lukasik R.N. James W. Freston M.D. Ph.D. F.A.C.G. 《The American journal of gastroenterology》2001,96(6):1704-1710
OBJECTIVE: Our objective was to compare four management strategies for heartburn: therapy with an H2-receptor antagonist (ranitidine), therapy with a proton pump inhibitor (lansoprazole), crossover from ranitidine to lansoprazole ("step-up" therapy), and crossover from lansoprazole to ranitidine ("step-down" therapy). METHODS: This was a controlled, double-blind, multicenter trial comprising 593 adults with heartburn, randomized to one of four groups for 20 wk. Subjects received either ranitidine 150 mg b.i.d. for 20 wk, or lansoprazole 30 mg once daily for 20 wk, or ranitidine 150 mg b.i.d. for 8 wk [corrected] followed by lansoprazole 30 mg once daily for 12 wk ("step-up"), or lansoprazole 30 mg once daily for 8 wk followed by ranitidine 150 mg b.i.d. for 12 wk ("step-down"). Outcome measures were based on self-reports in daily diaries of 24-h heartburn severity, measured by maximum daytime and nighttime severity, and percentage of 24-h heartburn-free days measured by absence of both daytime and nighttime heartburn. RESULTS: Median heartburn severity was significantly lower (p < 0.05) for lansoprazole (0.25) than the other groups (0.46 ranitidine, 0.44 "step-up," 0.35 "step-down"). The lansoprazole group had a significantly higher percentage of 24-h heartburn-free days (median 81.4%, p < 0.01) than other groups (66.6, 66.9, and 73.6%, respectively). In the "step-up" and "step-down" groups, heartburn was less severe, and percentages of 24-h heartburn-free days were higher during lansoprazole treatment regardless of treatment sequence. CONCLUSION: Proton pump inhibitor treatment provides more consistent heartburn relief than an H2-receptor antagonist, or "step-up" or "step-down" therapy. 相似文献
110.
Elizabeth A. Gilpin James A. Koziol Erling B. Madsen Hartmut Henning John Ross 《The American journal of cardiology》1983,52(3):240-244
The mortality rate after acute myocardial infarction (AMI) has generally been modeled by a single exponential function. The present study was undertaken to determine, in 3 different populations, whether or not periods exist during the first year after AMI which have mortality distributions that differ from this pattern. The 3 patient populations included San Diego (346 patients, 71 deaths), Vancouver (704 patients, 146 deaths), and Copenhagen (1,140 patients, 262 deaths). Hospital admission was within 24 hours of the onset of symptoms, and patients dying within the first 24 hours after hospital admission or of noncardiac or unknown causes were not analyzed. The mortality between 2 and 21 days in the combined data base was 11.4% (range 10.9 to 11.7) and from 3 weeks to 1 year 10.5% (range 9.0 to 11.3). A high degree of similarity was noted among the shapes of the 3 survival curves. The hypothesis of an exponential mortality rate during the entire first year was rejected. Using a special statistic, changepoints at days 17,23, and 24 in the 3 populations (21 days for the combined data base) were identified and used thereafter to divide the year into 2 separate periods of mortality within which exponentiality for the mortality rate was not rejected. The point by which exactly 50% of deaths had occurred was day 19, with 75% of deaths occurring by day 100. These data further define the natural history after AMI and indicate optimal follow-up periods for short- and longer-term management strategies based on risk assessment or trials of risk reduction after AMI. 相似文献